Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Verona Pharma (VRNA).
Verona Pharma plc has announced FDA approval of Ohtuvayre (ensifentrine) for treating chronic obstructive pulmonary disease (COPD) in adults, marking a significant milestone for the company. This innovative treatment, which uniquely combines bronchodilator and anti-inflammatory effects, promises ease of use through a standard jet nebulizer. Ohtuvayre, set to hit the market in Q3 2024, is expected to be distributed exclusively via accredited specialty pharmacies, making it a noteworthy development for investors tracking pharmaceutical innovations and market entries.
Find detailed analytics on VRNA stock on TipRanks’ Stock Analysis page.
